Vertex’s Viacyte Backs Out of CRISPR Diabetes Deal

Vertex still has an ongoing diabetes partnership with CRISPR, which gives it a non-exclusive license to the latter’s platform to develop a potential cure for type 1 diabetes.

Scroll to Top